Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modified chitosan having catechol group and biomedical material prepared from modified chitosan

A biomedical, catechol-based technology, applied in the field of chitosan, can solve the problems of high brittleness, poor water absorption, poor solubility, etc.

Inactive Publication Date: 2014-09-03
HAINAN JIANKE PHARMA
View PDF0 Cites 69 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in practical applications, a single chitosan not only has poor solubility, but also its products are brittle and poor in water absorption.
Yusof et al. prepared a single chitosan dressing, which can better prevent wound infection, but it is not suitable for the situation with more exudates due to poor water absorption and poor wound adhesion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified chitosan having catechol group and biomedical material prepared from modified chitosan
  • Modified chitosan having catechol group and biomedical material prepared from modified chitosan
  • Modified chitosan having catechol group and biomedical material prepared from modified chitosan

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0037] 1. Select dry chitosan powder with particle size less than 400 mesh, molecular weight greater than 200,000, and degree of deacetylation greater than 85%, 50g.

[0038] 2. Dissolve the above-mentioned dry powder in a 4% acetic acid solution at 60°C, keep stirring at this temperature, stop stirring after 36 hours, and filter the insoluble matter.

[0039] 3. Dissolve 5g of dopa or 3-(3,4-dihydroxy) phenylpropionic acid in water, add helium gas, add 2 times the amount of EDC condensing agent under the protection of helium gas, adjust the pH to 6-12, React overnight to prepare EDC ester.

[0040] 4. Disperse the EDC ester prepared in step 3 into the chitosan solution prepared in step 2, adjust the pH to 4-10, stir overnight, and let stand for 24 hours.

[0041] 5. Under vigorous stirring, add glutaraldehyde dropwise to the product obtained in the previous step to control the amount of glutaraldehyde to control the degree of cross-linking at 0.1-10%.

[0042] 6. Drop the product obta...

example 2

[0044] 1. Select dry chitosan powder with particle size less than 400 mesh, molecular weight greater than 200,000, and degree of deacetylation greater than 85%, 50g.

[0045] 2. Dissolve the above dry powder in a 4% acetic acid solution at 60°C, keep the temperature and stir, stop stirring after 36 hours, and filter the insoluble matter.

[0046] 3. Dissolve 5 g of dopamine in water, pass in helium gas, add 2 times the amount of epichlorohydrin under the protection of helium gas, adjust the pH to 5-12, and react overnight to prepare a grafted activator.

[0047] 4. Disperse the product prepared in step 3 into the chitosan solution prepared in step 2, adjust pH to 4-10, stir overnight, and let stand for 24 hours.

[0048] 5. Under vigorous stirring, add genipin dropwise to the product obtained in the upper step to control the amount of genipin and control the degree of crosslinking to 0.1-10%.

[0049] 6. The product obtained in the previous step is freeze-dried, and a hemostatic sponge ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a biomedical material and a product thereof. The biomedical material has main characteristic that a compound having a catechol group structure is grafted on chitosan to form a chitosan biomedical material having the catechol group structure; or the grafted chitosan is cross-linked to prepare a novel macromolecular biomedical material. The catechol has cell adhesion, so that tissue adhesiveness of the chitosan can be changed, and blood cells can be adsorbed on the material surface to achieve better bleeding-steeping effect. By virtue of the mediation, performance of the chitosan is improved, and tissue affinity is improved. The material is prepared into a novel bleeding-stopping sponge by freeze-drying, and prepared into novel dressing by spinning or prepared into powder dressing by reverse flocculating.

Description

technical field [0001] The invention relates to a chitosan with a catechol-based structure, which is a new biomedical material and can be used to make hemostatic sponges or various dressings. Background technique [0002] Chitosan is the deacetylated product of chitin (as shown in formula 1). It is the only natural alkaline polysaccharide found so far. It has no toxic and side effects and has great advantages as a drug carrier. At the same time, because of its good biocompatibility and biodegradability, chitosan has been widely used in medicine, food, environmental protection, light industry, agriculture, etc. Chitosan is used in medical dressings and has good physical and chemical properties and biological properties. Studies have shown that chitosan not only has good biocompatibility and biodegradability, but also has the functions of antibacterial, anti-inflammatory, hemostasis, reducing wound exudation and promoting wound tissue regeneration, repair and healing. But in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61L15/28A61L15/44A61L31/04A61L31/16A61L27/20A61L27/52A61L27/60C08J3/24C08L5/08C08B37/08
Inventor 杨顶建姜月霞
Owner HAINAN JIANKE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com